The cardiologist and kidney disease by Davids, M.R.
About one adult in ten, or over 500 million people worldwide, are affected with chronic kidney disease (CKD). 
This burden is expected to increase in parallel with the increase in diabetes, with the majority of cases occurring 
in the developing world. Many of these patients with CKD have progressive loss of renal function and will reach 
end-stage renal disease (ESRD) even if the original insult has been adequately addressed.
What may surprise many is the fact that premature death from cardiovascular disease is a much more common 
outcome than ESRD! CKD is increasingly being recognised as a very strong risk factor for cardiovascular disease, 
justifying lower targets for blood pressure and lipid control. In those patients who do survive to reach ESRD, and 
who have been accommodated on dialysis and transplant programmes, cardiovascular disease again is the leading 
cause of death.
In 2004 the International Society of Nephrology convened a meeting of experts in Bellagio, Italy, to address the 
problem of CKD. Organisations represented included the World Heart Federation, International Diabetes 
Federation, International Atherosclerosis Federation, and the International Society of Hypertension. It was resolved 
to develop an integrated global response for the prevention and treatment of chronic vascular diseases. The 
World Health Organisation has also emphasised the need for large coordinated, national programmes for the 
prevention, early detection and treatment of chronic diseases. These efforts would require government support 
and cooperation across different medical disciplines.
Against this background it is therefore timely that this issue of the Journal is devoted to the interface between 
nephrology and cardiology. Hopefully this will be the start of a trend toward more interaction and effective 
cooperation between colleagues, and professional societies, who often share the same patients as well as similar 
strategies for prevention and slowing of progression of disease.
In the fi rst article, Davids describes the magnitude and causes of the global epidemic of CKD. The epidemic of 
diabetes will contribute huge numbers of cases, and these will occur mainly in the developing world, where there 
are insuffi cient resources to deal with the most important complications, namely ESRD and advanced cardiovascular 
disease. In sub-Saharan Africa, a conservative approach to treating ESRD most often applies, with few patients 
able to gain access to chronic dialysis and renal transplantation. 
Katz et al discuss the integrated approach to prevention and treatment programmes for CKD and cardiovascular 
disease, reviewing the very successful initiative of Wendy Hoy with the Aboriginal Australians in the Northern 
Territory, and also their own project in Soweto. It is worth mentioning that Dr Nomandla Madala of the University 
of KwaZulu-Natal (KZN) has just been awarded funding by the International Society of Nephrology for her project 
on preserving renal function in patients with chronic non-communicable diseases in urban and rural KZN.
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Swanepoel focuses on the very topical issue of CKD as a powerful cardiovascular risk factor, pointing out the fact 
that patients with CKD have a high prevalence of cardiovascular disease as well as a very high mortality rate after 
acute cardiac events. Patients with CKD have multiple risk factors for the development of atherosclerosis, including 
several non-traditional risk factors like vascular and valvular calcifi cation, infl ammation and malnutrition, chronic 
anaemia and chronic fl uid overload. Most large studies of interventions for coronary artery disease have excluded 
patients with CKD and it remains unclear what the optimal treatment strategies are for these patients.
Acute renal failure (ARF) is frequently encountered in the cardiac intensive care unit, and its development usually 
signifi es a poor prognosis. Bihl and colleagues offer a practical approach to prevention and management, reviewing 
such topics as the RIFLE classifi cation of ARF, prevention of contrast nephropathy, and the management of 
established ARF, including renal replacement therapy.
The article by Adeniyi and Nel on renal involvement in infective endocarditis describes the spectrum of 
involvement from pre-renal failure to immune complex-mediated glomerulonephritis and provides practical 
advice on how to differentiate between the various causes.
Patients with severe heart failure have chronic fl uid overload combined with poor renal perfusion. The pre-renal 
failure that develops (the “cardio-renal syndrome”) is often exacerbated by our attempts to treat their 
diuretic-resistant oedema.  Krishnan and Oreopoulos have written an article which is likely to generate lots of 
discussion – they propose chronic ambulatory peritoneal dialysis (CAPD) as an effective means of addressing the 
volume overload, while possibly having less of a deleterious effect on renal function as compared to aggressive 
diuretic therapy. In the South African setting, CAPD may well be able to provide a life-saving bridge to patients 
awaiting cardiac transplantation.
I would like to thank all our contributors for helping to put together an issue that covers a lot of important 
ground, and which should prove useful to cardiologist and nephrologist alike. Finally, thanks is due to the SA Heart 
Journal, and its editor Anton Doubell, who fi rst put forward the idea of a “renal issue” and extended the invitation 
for me to act as guest editor. I hope that this contribution by members of the SA Renal Society to the offi cial 
journal of the SA Heart Association will be but the fi rst of many fruitful collaborative efforts between our two 
organisations.
